Galderma’s Epiduo gel (adapalene 0.1% and benzoyl peroxide 2.5%) is a topical acne treatment that combines adapalene, a retinoid, and benzoyl peroxide, an antimicrobial. In a 12-week, Phase 2 trial of 517 patients, Epiduo gel reduced the median number of total acne lesions by more than 50%, as compared to monotherapy with either adapalene (35.4 % reduction) or benzoyl peroxide (35.6% reduction) alone.
Epiduo is indicated for the treatment of acne vulgaris in patients ≥12 years of age. It is expected to be available in the first quarter of 2009.
For more information call (817) 961-5000 or visit www.galderma.com.